Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Levocarnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.80 |
| ▸ | CPT2 | P23786 | 2/20 | 0.52 |
| ▸ | CPT1A | P50416 | 2/20 | 0.52 |
| ▸ | CRAT | P43155 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carnitine SCHEMBL5712407 | 1.00 | SLC22A16 (0.80) | SLC22A16CPT2CPT1ACRATMAPT | |
| Levocarnitine SCHEMBL4523560 | 0.94 | SLC22A16 (0.83) | SLC22A16CPT2CPT1ACRATMAPT | |
| Carnitine SCHEMBL3680647 | 0.94 | SLC22A16 (0.83) | SLC22A16CPT2CPT1ACRATMAPT | |
| Carnitine SCHEMBL21971 | 0.89 | SLC22A16 (1.00) | SLC22A16CPT2CPT1ACRATMAPT | |
| D-Carnitine SCHEMBL94286 | 0.89 | SLC22A16 (1.00) | SLC22A16CPT2CPT1ACRATMAPT | |
| Levocarnitine SCHEMBL21970 | 0.89 | SLC22A16 (1.00) | SLC22A16CPT2CPT1ACRATMAPT | |
| Carnitine SCHEMBL3902633 | 0.89 | SLC22A16 (1.00) | SLC22A16CPT2CPT1ACRATMAPT | |
| Carnitine SCHEMBL1813524 | 0.89 | SLC22A16 (1.00) | SLC22A16CPT2CPT1ACRATMAPT | |
| Carnitine SCHEMBL17629811 | 0.89 | SLC22A16 (1.00) | SLC22A16CPT2CPT1ACRATMAPT | |
| Levocarnitine SCHEMBL4593172 | 0.89 | SLC22A16 (1.00) | SLC22A16CPT2CPT1ACRATMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | SILTI AG (CH) | 2024-02-29 | — | — | US | claimed |
| EP-3164125-B1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN GLOBAL LLC (US) | 2023-09-06 | — | — | EP | claimed |
| CN-113387836-A | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, or treating or preventing the development of diabetes | NAN全球有限责任公司 | 2021-09-14 | — | — | CN | claimed |
| US-20210186918-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2021-06-24 | — | — | US | claimed |
| EP-3164125-A2 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | Nan Global, LLC (US) | 2017-05-10 | — | — | EP | claimed |
| WO-2016004363-A2 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN Global, LLC (US) | 2016-01-07 | — | — | WO | claimed |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2016-01-07 | — | — | US | claimed |
| EP-1218001-B1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2008-12-31 | — | — | EP | claimed |
| US-7303765-B2 | Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2007-12-04 | — | — | US | claimed |
| US-20050124558-A1 | Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2005-06-09 | — | — | US | claimed |
| EP-1218001-A4 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2005-05-18 | — | — | EP | claimed |
| US-20020111383-A1 | Ultrafine L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2002-08-15 | — | — | US | claimed |
| EP-1218001-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | Sigma-Tau Healthscience S.p.A. (IT) | 2002-07-03 | — | — | EP | claimed |
| WO-2001017525-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA-TAU HEALTHSCUIENCE S.P.A (IT) | 2001-03-15 | — | — | WO | claimed |
| US-20240374552-A1 | Compositions and Methods for Preventing or Reducing the Risk of Metabolic Syndrome | GARCÍA SADA, FERNANDO (MX) | 2024-11-14 | — | — | US | disclosed |
| EP-4393486-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING THE RISK OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2024-07-03 | — | — | EP | disclosed |
| CN-118159260-A | Compositions and methods for preventing or reducing the risk of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-06-07 | — | — | CN | disclosed |
| US-20020111383-A1 | Ultrafine L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2002-08-15 | — | — | US | disclosed |
| EP-1218001-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | Sigma-Tau Healthscience S.p.A. (IT) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001017525-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA-TAU HEALTHSCUIENCE S.P.A (IT) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186918-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | SLC22A16 1032/4885CPT2 3/4885CPT1A 16/4885 |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | SLC22A16 1032/4885CPT2 3/4885CPT1A 16/4885 |
| US-20240374552-A1 | Compositions and Methods for Preventing or Reducing the Risk of Metabolic Syndrome | GPR119, GPR27, PTPN7 | SLC22A16 612/4885CPT2 684/4885CPT1A 151/4885 |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | SLC22A16 1032/4885CPT2 3/4885CPT1A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.